BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

938 related articles for article (PubMed ID: 27565523)

  • 1. Level of Fecal Calprotectin Correlates With Severity of Small Bowel Crohn's Disease, Measured by Balloon-assisted Enteroscopy and Computed Tomography Enterography.
    Arai T; Takeuchi K; Miyamura M; Ishikawa R; Yamada A; Katsumata M; Igarashi Y; Suzuki Y
    Clin Gastroenterol Hepatol; 2017 Jan; 15(1):56-62. PubMed ID: 27565523
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prediction of disease activity of Crohn's disease through fecal calprotectin evaluated by balloon-assisted endoscopy.
    Iwamoto F; Matsuoka K; Motobayashi M; Takenaka K; Kuno T; Tanaka K; Tsukui Y; Kobayashi S; Yoshida T; Fujii T; Saito E; Yamaguchi T; Nagahori M; Sato T; Ohtsuka K; Enomoto N; Watanabe M
    J Gastroenterol Hepatol; 2018 Dec; 33(12):1984-1989. PubMed ID: 29889986
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fecal Calprotectin More Accurately Predicts Endoscopic Remission of Crohn's Disease than Serological Biomarkers Evaluated Using Balloon-assisted Enteroscopy.
    Kawashima K; Ishihara S; Yuki T; Fukuba N; Sonoyama H; Kazumori H; Yamashita N; Tada Y; Kusunoki R; Oka A; Oshima N; Mishima Y; Moriyama I; Kinoshita Y
    Inflamm Bowel Dis; 2017 Nov; 23(11):2027-2034. PubMed ID: 28817462
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Computed tomography enterography versus balloon-assisted enteroscopy for evaluation of small bowel lesions in Crohn's disease.
    Tong JL; Feng Q; Shen J; Qiao YQ; Zheng Q; Gu Y; Chen XY; Li XB; Dai J; Hua J; Xu JR; Ran ZH
    J Gastroenterol Hepatol; 2013 Jul; 28(7):1180-6. PubMed ID: 23611043
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fecal calprotectin is a strong predictive marker of relapse in Chinese patients with Crohn's disease: a two-year prospective study.
    Ye L; Chen BQ; Wang SD; Shi H; Yang Z; Wang FY
    Scand J Gastroenterol; 2017 Oct; 52(10):1113-1119. PubMed ID: 28675068
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease.
    D'Haens G; Ferrante M; Vermeire S; Baert F; Noman M; Moortgat L; Geens P; Iwens D; Aerden I; Van Assche G; Van Olmen G; Rutgeerts P
    Inflamm Bowel Dis; 2012 Dec; 18(12):2218-24. PubMed ID: 22344983
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Associations Among Mucosal and Transmural Healing and Fecal Level of Calprotectin in Children With Crohn's Disease.
    Weinstein-Nakar I; Focht G; Church P; Walters TD; Abitbol G; Anupindi S; Berteloot L; Hulst JM; Ruemmele F; Lemberg DA; Leach ST; Cytter R; Greer ML; Griffiths AM; Turner D;
    Clin Gastroenterol Hepatol; 2018 Jul; 16(7):1089-1097.e4. PubMed ID: 29501599
    [TBL] [Abstract][Full Text] [Related]  

  • 8. EMerging BiomARKers in Inflammatory Bowel Disease (EMBARK) study identifies fecal calprotectin, serum MMP9, and serum IL-22 as a novel combination of biomarkers for Crohn's disease activity: role of cross-sectional imaging.
    Faubion WA; Fletcher JG; O'Byrne S; Feagan BG; de Villiers WJ; Salzberg B; Plevy S; Proctor DD; Valentine JF; Higgins PD; Harris JM; Diehl L; Wright L; Tew GW; Luca D; Basu K; Keir ME
    Am J Gastroenterol; 2013 Dec; 108(12):1891-900. PubMed ID: 24126633
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of noninvasive evaluations in monitoring inflammatory bowel disease activity: A prospective study in China.
    Chen JM; Liu T; Gao S; Tong XD; Deng FH; Nie B
    World J Gastroenterol; 2017 Dec; 23(46):8235-8247. PubMed ID: 29290660
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Low Fecal Calprotectin Correlates with Histological Remission and Mucosal Healing in Ulcerative Colitis and Colonic Crohn's Disease.
    Zittan E; Kelly OB; Kirsch R; Milgrom R; Burns J; Nguyen GC; Croitoru K; Van Assche G; Silverberg MS; Steinhart AH
    Inflamm Bowel Dis; 2016 Mar; 22(3):623-30. PubMed ID: 26829408
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Correlation between fecal calprotectin and inflammation in the surgical specimen of Crohn's disease.
    Pous-Serrano S; Frasson M; Cerrillo E; Beltrán B; Iborra M; Hervás D; García-Granero E; Nos P
    J Surg Res; 2017 Jun; 213():290-297. PubMed ID: 28601328
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inter- and intraobserver agreement in computed tomography enterography in inflammatory bowel disease.
    Horvat N; Tavares CC; Andrade AR; Cabral JC; Leao-Filho HM; Caiado AH; Ueda SK; Leite AZ; Sipahi AM; Rocha MS
    World J Gastroenterol; 2016 Dec; 22(45):10002-10008. PubMed ID: 28018107
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fecal Calprotectin in Ileal Crohn's Disease: Relationship with Magnetic Resonance Enterography and a Pathology Score.
    Cerrillo E; Beltrán B; Pous S; Echarri A; Gallego JC; Iborra M; Pamies J; Nos P
    Inflamm Bowel Dis; 2015 Jul; 21(7):1572-9. PubMed ID: 26052967
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fecal calprotectin and S100A12 have low utility in prediction of small bowel Crohn's disease detected by wireless capsule endoscopy.
    Sipponen T; Haapamäki J; Savilahti E; Alfthan H; Hämäläinen E; Rautiainen H; Koskenpato J; Nuutinen H; Färkkilä M
    Scand J Gastroenterol; 2012 Jul; 47(7):778-84. PubMed ID: 22519419
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Monitoring Crohn's disease activity: endoscopy, fecal markers and computed tomography enterography.
    Lopes S; Andrade P; Afonso J; Cunha R; Rodrigues-Pinto E; Ramos I; Macedo G; Magro F
    Therap Adv Gastroenterol; 2018; 11():1756284818769075. PubMed ID: 29760785
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of capsule endoscopy and fecal biomarkers in small-bowel Crohn's disease to assess remission and predict relapse.
    Aggarwal V; Day AS; Connor S; Leach ST; Brown G; Singh R; Friedman A; Zekry A; Craig PI
    Gastrointest Endosc; 2017 Dec; 86(6):1070-1078. PubMed ID: 28947363
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fecal calprotectin for the prediction of small-bowel Crohn's disease by capsule endoscopy: a systematic review and meta-analysis.
    Kopylov U; Yung DE; Engel T; Avni T; Battat R; Ben-Horin S; Plevris JN; Eliakim R; Koulaouzidis A
    Eur J Gastroenterol Hepatol; 2016 Oct; 28(10):1137-44. PubMed ID: 27415156
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fecal calprotectin measurement is a marker of short-term clinical outcome and presence of mucosal healing in patients with inflammatory bowel disease.
    Kostas A; Siakavellas SI; Kosmidis C; Takou A; Nikou J; Maropoulos G; Vlachogiannakos J; Papatheodoridis GV; Papaconstantinou I; Bamias G
    World J Gastroenterol; 2017 Nov; 23(41):7387-7396. PubMed ID: 29151692
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A prospective study of fecal calprotectin and lactoferrin as predictors of small bowel Crohn's disease in patients undergoing capsule endoscopy.
    Bar-Gil Shitrit A; Koslowsky B; Livovsky DM; Shitrit D; Paz K; Adar T; Adler SN; Goldin E
    Scand J Gastroenterol; 2017 Mar; 52(3):328-333. PubMed ID: 27841040
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fecal calprotectin correlates more closely with the Simple Endoscopic Score for Crohn's disease (SES-CD) than CRP, blood leukocytes, and the CDAI.
    Schoepfer AM; Beglinger C; Straumann A; Trummler M; Vavricka SR; Bruegger LE; Seibold F
    Am J Gastroenterol; 2010 Jan; 105(1):162-9. PubMed ID: 19755969
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 47.